Gland Pharma Share Price Target Forecast 2022, 2023, 2025, 2030

DECEMBER 1, 2021

Emkay Global Financial: Gland Pharma Share Price Target 2022; Buy For Rs 5000

Emkay Global Financial is bullish on Gland Pharma, recommending a Buy rating on the company with a target price of Rs 5000 in its Research Report dated November 29, 2021.

Gland Pharma Management came to Mumbai for a two-day non-deal roadshow to meet investors. The company’s distinctive business strategy, which is likely to gain from growing competition in generic injectables, is bolstered by management comments.

While the firm continues to develop its product range for longstanding clients such as Apotex, Fresenius Kabi, and Pfizer (Hospira), it is also gaining momentum with newcomers to the US generic injectables market, such as Alembic Pharma.

The Biologics business, according to management, is a natural extension of its injectable capabilities. While it may have to rely on its parent firm, Fosun Pharma, at first, the company hopes to establish a friendlier business by utilising its current customer ties.

Outlook

Due to strong growth and visibility into profitability, we remain bullish on Gland Pharma. We expect a 25 percent/25 percent/27 percent CAGR in revenue, EBITDA, and net profit (FY21- 24e). Gland’s industry-leading return ratio will be boosted even more by strong growth.

Moneycontrol.com is the source for this information.


30 NOVEMBER 2021

Sharekhan’s price target for Gland Pharma is 2022, with a buy price of Rs 4400.

Sharekhan is positive on Gland Pharma, recommending a BUY rating on the company with a target price of Rs 4400 in its November 26, 2021 research report.

Over the next 3-4 years, Gland expects to expand the percentage of sales from ROW countries to 40% (now 21%), owing to significant growth in China markets and increasing penetration in existing ROW regions.

The core market segment’s performance will be driven by a well-diversified product portfolio, a strong product pipeline, and a strengthening base business in the United States. Gland has gotten closer to its long-term goal of entering the lucrative biosimilar CDMO market thanks to the vaccine manufacturing possibility.

Outlook

With a PT of 4,400, we reiterate our BUY recommendation on Gland Pharma (Gland).

Moneycontrol.com is the source for this information.


30 SEPTEMBER 2021

Sharekhan’s price target for Gland Pharma is Rs 4400.

Sharekhan is bullish on Gland Pharma, recommending a BUY rating on the stock with a target price of Rs 4400 in a research report dated September 29, 2021.

The success of core markets will be driven by a highly-diversified product portfolio and a robust innovation pipeline, while extending global footprint with intentions to enter China bodes well for growth. Gland’s aspirations to enter the biosimilar CDMO industry and opportunities for the Sputnik vaccine will be important growth drivers. Gland spent Rs 770 crore on capital expenditures in FY22E-FY23E, which could help it fulfil rising demand for both old and new goods.

Outlook

We maintain our buy rating on Gland Pharma (Gland), with a price target of Rs 4400. The stock price has dropped 14% from its highs, making it a suitable entry position for investors.

Moneycontrol.com is the source for this information.


AUGUST 6, 2021

Motilal Oswal’s share price target for Gland Pharma is Rs 4460.

In its research report dated July 22, 2021, Motilal Oswal is positive on the BUY rating offered by Gland Pharma on the company, with a target price of Rs 4460.

Gland outperformed our expectations in the first quarter of FY22, thanks to strong revenue growth across all geographies. The COVID-19 vaccine is progressing well in terms of scaling up production. It is increasing its geographical diversification while also developing concurrent product/complex product related capital expenditure.

For each of the following reasons, we raise our FY22E/FY23E EPS estimate by 8%: a) increasing penetration, including penetration into the ROW/India markets; b) a better outlook for the US market; and c) remdesivir/enoxaparin. Higher offtake, as well as d) improved production efficiency and operational leverage.

Outlook

To get to our target price of INR4,460, we value GLAND at 35 times its 12-month future earnings. We continue to be bullish on Gland owing to: a) increased ramp-up of current products, b) robust manufacturing in the complex product pipeline, c) continuous investments in the vaccine/organic domain, and d) significant inorganic growth potential. We maintain our buy recommendation.

Moneycontrol.com is the source for this information.


06 JULY 2021

Sharekhan’s price target for Gland Pharma is Rs 4100.

Sharekhan is bullish on Gland Pharma, recommending a BUY rating on the company with a target price of Rs 4100 in a research report dated July 5, 2021.

Gland’s primary market area is performing well, with double-digit growth forecast in US markets. Key growth drivers are increasing prospects in Chinese markets and vaccination regime opportunities. Gland has strong domain expertise and growth prospects, as well as a strong earnings track record and strong financials, with earnings expected to grow at a 39 percent CAGR from FY21 to FY2023E.

Outlook

Gland Pharma (Gland) remains a buy recommendation, with a revised PT of Rs 4,100.

Moneycontrol.com is the source for this information.


Disclaimer: The views and investment tips expressed by investment expert on Stock consultant bihar are Sourced From Brokerage Firms Research Reports & Market Experts Opinion. We advises users to consult your investment advisor before taking any decisions. Our Website Contain Demat Account & Algo Trading affliate Link. If You’ll Register Through Our Link We May Get Profit.

More Share Price Target Updates:

We will be happy to hear your thoughts

Leave a reply

Stock Consultant Bihar
Logo